After 11 years in pharma commercial strategy, I’ve sat through thousands of hours of conference programming. I’ve seen teams blow entire budgets on "must-attend" events that resulted in nothing more than a few mediocre LinkedIn photos and a stack of business cards that ended up in the recycling bin. If you are a Market Access lead, you shouldn’t be "attending" conferences. You should be executing a strategic plan. Every ticket you expense should map directly to a commercial milestone—whether that’s a breakthrough in payer discussions, a deep dive into pricing pressure, or validating your value proposition via outcomes research.
If you find yourself calling every annual gathering a "must-attend," stop. You aren’t being strategic; you’re being a tourist. Let’s clean up your portfolio.
The ISPOR Litmus Test: Why You Are Actually There
ISPOR is the Mecca for HEOR (Health Economics and Outcomes Research). If you aren’t there, you aren’t in the conversation. But the danger with ISPOR is worldpharmatoday.com getting lost in the weeds of technical methodology while forgetting your commercial objective.
When you walk onto the floor, your goal isn't to watch every poster session. It’s to stress-test your value story. Are your outcomes research data points holding water against the specific pricing pressure trends being discussed by national payers? Are your models resonating, or are they being picked apart for lacking real-world relevance?
The "Meetings That Look Big But Do Nothing" List
In my decade-plus of experience, I’ve kept a running list of meetings that look impressive on a team calendar but provide zero ROI for a market access team:
- The "Generic Thought Leadership" Panel: If the speakers are all consultants talking about "The Future of Access" without citing specific policy shifts or legislative movement, walk out. The Massive Networking Reception: You cannot have a high-stakes payer discussion in a room with 400 people and an open bar. If you’re trying to move a needle on a formulary, find the quiet corner or the private breakout, not the crowded gala. The "Big Picture" Keynote: Unless the keynote involves a CMS official or a lead architect of a major PBM policy change, it’s fluff. Don't waste your morning there.
Anchoring Your Strategy: A Portfolio Approach
A smart market access portfolio isn't about collecting badges; it's about sequencing your year to support the product lifecycle. Here is how I organize a high-performing annual calendar using specialized tools and focused events.
1. The Summer Anchor: BIO Partnering (The BD/Licensing Engine)
I view the BIO International Convention as the primary engine for licensing and strategic partnerships. For Market Access teams, this is where you pressure-test your commercial viability early. Use the BIO Partnering platform not just for buying/selling assets, but for scoping the competitive landscape. If you are looking to acquire or co-promote, the partnering meetings allow you to bypass the noise and speak directly with the principals. The goal here is efficiency. If you leave BIO without a clear "Yes" or "No" on a potential partnership lead, you used the platform as a rolodex rather than a surgical tool.
2. Competitive Intelligence: Fierce Pharma Week
Market access is often fought in the dark—you rarely see your competitor’s true pricing strategy until the PBMs make a decision. Fierce Pharma Week is where you go to triangulate what your competitors are saying vs. what they are doing. This is the place for competitive intelligence. You aren't there for the brand fluff; you’re there to identify shifts in their commercial narrative. If they’ve changed their language around "patient assistance programs" or "rebate transparency," you need to know how that impacts your own strategy before the next contracting cycle begins.
3. Formulary Reality: The Health Management Academy (THMA)
If you want to know what’s happening in health systems and IDNs, you need to be in the room with The Health Management Academy. This is not a standard "trade show." This is where you hear from the stakeholders who actually manage the pharmacy budget at the executive level. THMA provides the kind of direct line into health system leadership that you simply cannot get at the massive, global academic meetings. Use these forums to test your payer discussions. Ask them: "If I present this data, does it move the needle on your formulary, or does it just create more administrative work?"
Strategic Evaluation Checklist
Before you approve travel or purchase a registration, put the event through this simple, brutal checklist. If you can’t answer "Yes" to at least three, don't go.
Criteria The Test Clear Commercial Objective Does this event solve a specific hurdle for my current launch or contracting cycle? Access to Decision Makers Are the specific payers or health system leaders I need to influence actually on the guest list? Concrete Intel Capture Will I walk away with at least three insights on competitor pricing or policy shifts? No "Fluff" Factor Are the panels focused on tangible policy/data, or are they high-level marketing platitudes?Why ROI Claims Usually Lie
I hear it every year: "We had a great presence, and the networking was high-quality." That is marketing-speak for "we spent a lot of money and I have no idea what we achieved."
If you want to measure ROI in market access, stop looking for "attendee counts." Look for these outcomes:
Insight Validation: Did you test your value story against a payer and refine it based on their feedback? Competitive Foresight: Did you gain information that allowed you to adjust your launch strategy at least 3 months earlier than planned? Partnering Velocity: Did you shorten the timeline of a potential deal by using an platform like BIO effectively?The Final Word: Stop Collecting Badges
Market Access is a high-stakes chess match. You don’t play chess by wandering into as many rooms as possible—you play by positioning your pieces on the board where they matter most. Before you book your next flight, ask yourself if the event helps you win a specific square on the board or if it’s just a way to feel busy. Your budget is finite. Spend it where the decisions happen, not where the marketing banners are the largest.
Remember: If you can't articulate exactly why an event is necessary to move your product's market access strategy forward, it’s not a strategic asset. It’s an expense. Cut it.